News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Immunic to present additional Phase 2 CALLIPER Trial data for Vidofludimus Calcium at CMSC Annual Meeting 2026, reinforcing its potential in progressive multiple sclerosis -
-
-
COMMUNIQUÉ DE PRESSE
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
Immunic appoints Erik Lundgren as CEO to lead transition to commercial-stage MS company. Lundgren's extensive biopharmaceutical experience brings strategic and operational expertise to Immunic -